ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

GVHD: Importance of Early Detection and Management

Ernst Holler

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

Correlation of PROs and Organ Response in Belumosudil-Treated cGVHD:…

Levanto Schachter

Understanding New Strategies to Prevent and Manage Chronic GVHD

2024 ASCO® Annual Meeting Insights Hub

B. Hamilton

CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD

Najla El-Jurdi

The Role of CSF1R in Modulating Inflammation and Fibrosis

Fred Hutchinson Cancer Center

R. Adams

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

Approaches to Preventing and Treating GVHD in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

N. Hossain

Maintaining QoL in Chronic GvHD

Nandita Khera

Current and Future Therapeutic Approaches to cGVHD

Kirk Schultz

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

ecancer

M. Al Malki, S. Devine

Yale Cancer Center Allogeneic Stem Cell Transplantation Updates

Yale Cancer Center

L. Bachegowda

Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other…

Brittany Ragon

Navigating aGVHD Treatment: Integrating Recent Updates in Clinical M…

Icahn School of Medicine at Mount Sinai

J. Ferrara

The Evolving Landscape of cGVHD Treatment Options

Giuseppe Francesco Milone

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry